The novel biomarker of alternative macrophage activation, soluble mannose receptor (sMR/sCD206): Implications in multiple myeloma

Leukemia Research

Volumn 39, Issue 9, 2015, Pages 971-975

  Andersen, Morten N ^a,b   Andersen, Niels F ^a   Rødgaard Hansen, Sidsel ^a   Hokland, Marianne ^b   Abildgaard, Niels ^c   Møller, Holger J ^a  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

^b AARHUS UNIVERSITY   (Denmark)

^c ODENSE UNIVERSITY HOSPITAL   (Denmark)

Author keywords

Biomarker; Bone marrow microenvironment; Macrophage; Mannose receptor; Multiple myeloma; SCD206; SMR

Indexed keywords

BIOLOGICAL MARKER; C REACTIVE PROTEIN; CD163 ANTIGEN; CREATININE; MANNOSE RECEPTOR; ANTINEOPLASTIC AGENT; CELL SURFACE RECEPTOR; DIFFERENTIATION ANTIGEN; LECTIN; LEUKOCYTE ANTIGEN; MANNOSE BINDING LECTIN; MELPHALAN; PREDNISONE; TUMOR MARKER;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; CANCER PROGNOSIS; CARCINOGENESIS; CONTROLLED STUDY; DISEASE ASSOCIATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; KAPLAN MEIER METHOD; LOG RANK TEST; MACROPHAGE ACTIVATION; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; MULTIPLE MYELOMA; MULTIVARIATE ANALYSIS; OVERALL SURVIVAL; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; PROTEIN BLOOD LEVEL; REGRESSION ANALYSIS; VERY ELDERLY; BLOOD; COHORT ANALYSIS; DRUG EFFECTS; GENE EXPRESSION; GENETICS; IMMUNOLOGY; MACROPHAGE; MIDDLE AGED; MORTALITY; PATHOLOGY; PROGNOSIS; SOLUBILITY; SURVIVAL; TUMOR MICROENVIRONMENT;

ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, CD; ANTIGENS, DIFFERENTIATION, MYELOMONOCYTIC; ANTINEOPLASTIC AGENTS; COHORT STUDIES; FEMALE; GENE EXPRESSION; HUMANS; LECTINS, C-TYPE; MACROPHAGE ACTIVATION; MACROPHAGES; MALE; MANNOSE-BINDING LECTINS; MELPHALAN; MIDDLE AGED; MULTIPLE MYELOMA; MULTIVARIATE ANALYSIS; PREDNISONE; PROGNOSIS; RECEPTORS, CELL SURFACE; SOLUBILITY; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL; TUMOR MICROENVIRONMENT;

EID: 84940953652     PISSN: 01452126     EISSN: 18735835     Source Type: Journal    
DOI: 10.1016/j.leukres.2015.06.003     Document Type: Article

References (28)

1. Kyle R.A., Steensma D.P. History of multiple myeloma. Recent Results Cancer Res. 2011, 183:3-23.
2. Qian B.-Z., Pollard J.W. Macrophage diversity enhances tumor progression and metastasis. Cell 2010, 141:39-51.
3. Asimakopoulos F., Kim J., Denu R.A., Hope C., Jensen J.L., Ollar S.J., et al. Macrophages in multiple myeloma: emerging concepts and therapeutic implications. Leuk Lymphoma 2013, 54:2112-2121.
4. Sica A., Allavena P., Mantovani A. Cancer related inflammation: the macrophage connection. Cancer Lett. 2008, 267:204-215.
5. Suyani E., Sucak G.T., Akyürek N., Sahin S., Baysal N.A., Yağci M., et al. Tumor-associated macrophages as a prognostic parameter in multiple myeloma. Ann. Hematol. 2013, 92:669-677.
6. Zheng Y., Cai Z., Wang S., Zhang X., Qian J., Hong S., et al. Macrophages are an abundant component of myeloma microenvironment and protect myeloma cells from chemotherapy drug-induced apoptosis. Blood 2009, 114:3625-3628.
7. Zheng Y., Yang J., Qian J., Qiu P., Hanabuchi S., Lu Y., et al. PSGL-1/selectin and ICAM-1/CD18 interactions are involved in macrophage-induced drug resistance in myeloma. Leukemia 2012, 27:702-710.
8. Porcheray F., Viaud S., Rimaniol A.-C., Léone C., Samah B., Dereuddre-Bosquet N., et al. Macrophage activation switching: an asset for the resolution of inflammation. Clin. Exp. Immunol. 2005, 142:481-489.
9. Vogel D.Y.S., Glim J.E., Stavenuiter A.W.D., Breur M., Heijnen P., Amor S., et al. Human macrophage polarization in vitro: maturation and activation methods compared. Immunobiology 2014, 219:695-703.
10. Mantovani A., Sica A., Sozzani S., Allavena P., Vecchi A., Locati M. The chemokine system in diverse forms of macrophage activation and polarization. Trends Immunol. 2004, 25:677-686.
11. Duluc D., Duluc D., Delneste Y., Delneste Y., Tan F., Tan F., et al. Tumor-associated leukemia inhibitory factor and IL-6 skew monocyte differentiation into tumor-associated macrophage-like cells. Blood 2007, 110:4319-4330.
12. Pollard J.W. Opinion: tumour-educated macrophages promote tumour progression and metastasis. Nat. Rev. Cancer 2004, 4:71-78.
13. Gordon S. Alternative activation of macrophages. Nat. Rev. Immunol. 2003, 3:23-35.
14. Biswas S.K., Mantovani A. Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm. Nat. Immunol. 2010, 11:889-896.
15. Martínez-Pomares L. The mannose receptor. J. Leukoc. Biol. 2012, 92:1177-1186.
16. Cook J., Hagemann T. Tumour-associated macrophages and cancer. Curr. Opin. Pharmacol. 2013, 13:595-601.
17. Solinas G., Schiarea S., Liguori M., Fabbri M., Pesce S., Zammataro L., et al. Tumor-conditioned macrophages secrete migration-stimulating factor: a new marker for M2-polarization, influencing tumor cell motility. J. Immunol. 2010, 185:642-652.
18. Allavena P., Chieppa M., Bianchi G., Solinas G., Fabbri M., Laskarin G., et al. Engagement of the mannose receptor by tumoral mucins activates an immune suppressive phenotype in human tumor-associated macrophages. Clin. Dev. Immunol. 2010, 2010:547179.
19. Martinez-Pomares L., Mahoney J.A., Kaposzta R., Linehan S.A., Stahl P.D., Gordon S. A functional soluble form of the murine mannose receptor is produced by macrophages in vitro and is present in mouse serum. J. Biol. Chem. 1998, 273:23376-23380.
20. Rødgaard-Hansen S., Rafique A., Christensen P.A., Maniecki M.B., Sandahl T.D., Nexø E., et al. A soluble form of the macrophage-related mannose receptor (MR/CD206) is present in human serum and elevated in critical illness. Clin. Chem. Lab. Med. 2014, 52:453-461.
21. Joyce J.A., Pollard J.W. Microenvironmental regulation of metastasis. Nat. Rev. Cancer 2008, 9:239-252.
22. Møller H.J. Soluble CD163. Scand. J. Clin. Lab. Invest. 2012, 72:1-13.
23. Andersen M.N., Abildgaard N., Maniecki M.B., Møller H.J., Andersen N.F. Monocyte/macrophage-derived soluble CD163: a novel biomarker in multiple myeloma. Eur. J. Haematol. 2014, 93:41-47.
24. Beider K., Bitner H., Leiba M., Gutwein O., Koren-Michowitz M., Ostrovsky O., et al. Multiple myeloma cells recruit tumor-supportive macrophages through the CXCR4/CXCL12 axis and promote their polarization toward the M2 phenotype. Oncotarget 2015, 5:11283-11296.
25. Rey-Giraud F., Hafner M., Ries C.H. In vitro generation of monocyte-derived macrophages under serum-free conditions improves their tumor promoting functions. PLoS ONE 2012, 7:e42656.
26. Etzerodt A., Maniecki M.B., Moller K., Møller H.J., Moestrup S.K. Tumor necrosis factor-converting enzyme (TACE/ADAM17) mediates ectodomain shedding of the scavenger receptor CD163. J. Leukoc. Biol. 2010, 88:1201-1205.
27. Ramani V.C., Sanderson R.D. Chemotherapy stimulates syndecan-1 shedding: a potentially negative effect of treatment that may promote tumor relapse. Matrix Biol. 2014, 35:215-222.
28. Gazi U., Rosas M., Singh S., Heinsbroek S., Haq I., Johnson S., et al. Fungal recognition enhances mannose receptor shedding through dectin-1 engagement. J. Biol. Chem. 2011, 286:7822-7829.